ПЕРСПЕКТИВЫ ИСПОЛЬЗОВАНИЯ микроРНК В КАЧЕСТВЕ ДИАГНОСТИЧЕСКИХ И ПРОГНОСТИЧЕСКИХ БИОМАРКЕРОВ МЕЛАНОМЫ

Несмотря на недавние достижения таргетной и иммунной терапии, 5‑летняя общая выживаемость при постановке диагноза меланомы на III–IV стадии составляет 50 и 10–20 % соответственно. Cовременные биомаркеры меланомы, которые используются в клинической практике, не обладают достаточной эффективностью при ранней диагностике и оценке прогноза. В последнее десятилетие циркулирующие микроРНК (миРНК) все чаще стали рассматриваться в качестве идеальных биомаркеров меланомы. В данной статье представлены особенности биогенеза миРНК, а также приведен критический обзор циркулирующих миРНК как перспективных диагностических и прогностических биомаркеров меланомы.

1. Mumford S.L., Towler B.P., Pashler A.L. et al. Circulating MicroRNA biomarkers in melanoma: tools and challenges in personalised medicine. Biomolecules 2018;8(2):21. DOI: 10.3390/biom8020021.

2. Cancer Research UK Melanoma Survival (accessed on 13 January 2018). Available on: http://www. cancerresearchuk.org/about-cancer/melanoma/survival.

3. Finck S.J., Giuliano A.E., Morton D.L. LDH and melanoma. Cancer 1983;51(5):840–3. DOI: 10.1002/1097-0142(19830301)51: 5<840::AID-CNCR28205-10516>3.0.CO;2-7.

4. Deichmann M., Benner A., Bock M. et al. S100-β, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 1999;17(6):1891–6. DOI: 10.1200/JCO.1999.17.6.1891.

5. Karonidis A., Mantzourani M., Gogas H., Tsoutsos D. Serum S100-β levels correlate with stage, N status, mitotic rate and disease outcome in melanoma patients independent to LDH. J Buon 2017;22(5):1296–302.

6. Lee R.C., Feinbaum R.L., Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993;75(5):843–54. DOI: 10.1016/0092-8674(93)90529-y.

7. Carmell M.A., Xuan Z., Zhang M.Q., Hannon G.J. The Argonaute family: tentacles that reach into RNAi, developmental control, stem cell maintenance, and tumorigenesis. Genes Dev 2002;16(21):2733–42. DOI: 10.1101/gad.1026102.

8. Okamura K., Phillips M.D., Tyler D.M. et al. The regulatory activity of microRNA* species has substantial influence on microRNA and 3’ UTR evolution. Nat Struct Mol Biol 2008;15(4):354–63. DOI: 10.1038/nsmb.1409.

9. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116(2):281–97.

10. Рябчиков Д.А., Абдуллаева Э.И., Дудина И.А. и др. Роль микро-РНК в канцерогенезе и прогнозе злокачественных новообразований молочной железы. Вестник Российского научного центра рентгенорадиологии Минздрава России 2018;18(2):1–20. Доступно по: http://vestnik.rncrr.ru/vestnik/v18/docs/ryabchikov.pdf.

11. Lee Y., Ahn C., Han J. et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003;425(6956):415–9. DOI: 10.1038/nature01957.

12. Iwasaki S., Kobayashi M., Yoda M. et al. Hsc70/Hsp90 chaperone machinery mediates ATP-dependent RISC loading of small RNA duplexes. Mol Cell 2010;39(2):292–9. DOI: 10.1016/j.molcel.2010.05.015.

13. Kawamata T., Tomari Y. Making RISC. Trends Biochem Sci 2010;35(7):368–76. DOI: 10.1016/j.tibs.2010.03.009.

14. Kwak P.B., Tomari Y. The N domain of Argonaute drives duplex unwinding during RISC assembly. Nat Struct Mol Biol 2012;19(2):145–51. DOI: 10.1038/nsmb.2232.

15. Khvorova A., Reynolds A., Jayasena S.D. Functional siRNAs and miRNAs exhibit strand bias. Cell 2003;115(2):209–16. DOI: 10.1016/S0092-8674(03)00801-8.

16. Macfarlane L.A., Murphy P.R. MicroRNA: Biogenesis, Function and Role in Cancer. Curr Genomics 2010;11(7):537–61. DOI: 10.2174/138920210793175895.

17. Selbach M., Schwanhausser B., Thierfelder N. et al. Widespread changes in protein synthesis induced by microRNAs. Nature 2008;455:58–63. DOI: 10.1038/nature07228.

18. Sohel M.H. Extracellular/Circulating MicroRNAs: Release Mechanisms, Functions and Challenges. Achiev Life Sci 2016;10:175–86. DOI: 10.1016/j.als.2016.11.007.

19. Romano G., Kwong L.N. miRNAs, melanoma and microenvironment: an intricate network. Int J Mol Sci 2017;18(11):2354. DOI: 10.3390/ijms18112354.

20. Leidinger P., Keller A., Borries A. et al. High-throughput miRNA profiling of human melanoma blood samples. BMC Cancer 2010;10:262. DOI: 10.1186/1471-2407-10-262.

21. Van Laar R., Lincoln M., van Laar B. Development and validation of a plasmabased melanoma biomarker suitable for clinical use. Br J Cancer 2018;118:857–66. DOI: 10.1038/bjc.2017.477.

22. Margue C., Reinsbach S., Philippidou D. et al. Comparison of a healthy miRNome with melanoma patient miRNomes: are microRNAs suitable serum biomarkers for cancer? Oncotarget 2015;6:12110–27. DOI: 10.18632/oncotarget.3661.

23. Fogli S., Polini B., Carpi S. et al. Identification of plasma microRNAs as new potential biomarkers with high diagnostic power in human cutaneous melanoma. Tumour Biol 2017;39(5):1010428317701646. DOI: 10.1177/1010428317701646.

24. Philippidou D., Schmitt M., Moser D. et al. Signatures of microRNAs and selected microRNA target genes in human melanoma. Cancer Res 2010;70(10):4163–73. DOI: 10.1158/0008-5472.CAN-09-4512.

25. Greenberg E., Besser M.J., Ben-Ami E. et al. A comparative analysis of total serum miRNA profiles identifies novel signature that is highly indicative of metastatic melanoma: a pilot study. Biomarkers 2013;18:502–8. DOI: 10.3109/1354750X.2013.816777.

26. Satzger I., Mattern A., Kuettler U. et al. MicroRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma. Int J Cancer 2010;126(11):2553–62. DOI: 10.1002/ijc.24960.

27. Xu Y., Brenn T., Brown E.R. et al. Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors. Br J Cancer 2012;106(3):553–61. DOI: 10.1038/bjc.2011.568.

28. Kozubek J., Ma Z., Fleming E. et al. Indepth characterization of microRNA transcriptome in melanoma. PLoS One 2013;8(9):72699. DOI: 10.1371/journal.pone.0072699.

29. Alegre E., Sanmamed M.F., Rodriguez C. et al. Study of circulating microRNA-125b levels in serum exosomes in advanced melanoma. Arch Pathol Lab Med 2014;138(6):828–32. DOI: 10.5858/arpa.2013-0134-OA.

30. Achberger S., Aldrich W., Tubbs R. et al. Circulating immune cell and microRNA in patients with uveal melanoma developing metastatic disease. Mol Immunol 2014;58:182–6. DOI: 10.1016/j.molimm.2013.11.018.

31. Fleming N.H., Zhong J., da Silva I.P. et al. Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients. Cancer 2015;121(1):51–9. DOI: 10.1002/cncr.28981.

32. Friedman E.B., Shang S., de Miera E.V. et al. Serum microRNAs as biomarkers for recurrence in melanoma. J Transl Med 2012;10:155. DOI: 10.1186/1479-5876-10-155.

33. Stark M.S., Bonazzi V.F., Boyle G.M. et al. miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma. Oncotarget 2015;6(19):17753–63.

34. Garbe C., Eigentler T.K. Diagnosis and treatment of cutaneous melanoma: State of the art 2006. Melanoma Res 2007;17:117–27. DOI: 10.1097/CMR.0b013e328042bb36.

35. Hanniford D., Segura M.F., Zhong J. et al. Identification of metastasis-suppressive microRNAs in primary melanoma. JNCI J Natl Cancer Inst 2015;107(3):494. DOI: 10.1093/jnci/dju494.

36. Saldanha G., Elshaw S., Sachs P. et al. microRNA-10b is a prognostic biomarker for melanoma. Mod Pathol 2016;29(2):112–21. DOI: 10.1038/modpathol.2015.149.

37. Qi M., Huang X., Zhou L., Zhang J. Identification of differentially expressed microRNAs in metastatic melanoma using next-generation sequencing technology. Int J Mol Med 2014;33(5):1117–21. DOI: 10.3892/ijmm.2014.1668.

38. Armand-Labit V., Meyer N., Casanova A. et al. Identification of a circulating microRNA profile as a biomarker of metastatic cutaneous melanoma 2016; Acta Derm Venereol 96(1):29–34.

39. Cui L., Li Y., Lv X. et al. Expression of microRNA-301a and its functional roles in malignant melanoma. Cell Physiol Biochem 2016;40(1–2):230–44. DOI: 10.1159/000452540.

40. Bai J., Zhang Z., Li X., Liu H. MicroRNA-365 inhibits growth, invasion and metastasis of malignant melanoma by targeting NRP1 expression. Int J Clin Exp Pathol 2015;8(5):4913–22.